Are phosphodiesterase type 5 inhibitors effective for the management of lower urinary symptoms suggestive of benign prostatic hyperplasia? - Wikidata - wikimedia - TriplyDB

Are phosphodiesterase type 5 inhibitors effective for the management of lower urinary symptoms suggestive of benign prostatic hyperplasia?

Are phosphodiesterase type 5 inhibitors effective for the management of lower urinary symptoms suggestive of benign prostatic hyperplasia?

http://www.wikidata.org/entity/Q35050805

about

A synopsis of drugs currently in preclinical and early clinical development for the treatment of benign prostatic hyperplasia.

P2860

Q38485721-404064C9-7CD2-4A34-9C70-19461777034F

P2860

Are phosphodiesterase type 5 inhibitors effective for the management of lower urinary symptoms suggestive of benign prostatic hyperplasia?

http://www.wikidata.org/entity/Q35050805

description

2015 nî lūn-bûn

@nan

2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Are phosphodiesterase type 5 i ...... benign prostatic hyperplasia?

@ast

Are phosphodiesterase type 5 i ...... benign prostatic hyperplasia?

@en

type

label

Are phosphodiesterase type 5 i ...... benign prostatic hyperplasia?

@ast

Are phosphodiesterase type 5 i ...... benign prostatic hyperplasia?

@en

prefLabel

Are phosphodiesterase type 5 i ...... benign prostatic hyperplasia?

@ast

Are phosphodiesterase type 5 i ...... benign prostatic hyperplasia?

@en

P1433

Q35050805-FB597F35-6EAD-4445-81A2-23A174313962

P1476

Q35050805-10CB45B6-E7C1-4857-A9F1-38F33175543E

P2093

Q35050805-9A789CD7-E34B-493B-95C8-49D07FE66F23

Q35050805-F716B434-0571-4A36-938C-FB46DA9B7BC6

P2860

Q35050805-0F536323-1928-41C9-8042-4411A19841E9

Q35050805-12AD50BC-E95C-4F67-A31B-775849F8DEF1

Q35050805-158C7C9E-5812-4E9C-A10B-D7084D6C6B9C

Q35050805-16952169-FC72-4416-ADE3-528F9EDF4835

Q35050805-2BF8EBB9-8239-4804-9BCA-FDC9DF2AB515

Q35050805-33863403-C6A9-4BE1-9231-FAC9CC3B68B6

Q35050805-33C5A041-EB98-433C-AFB7-4990E3BE05EE

Q35050805-4761A5A1-AD16-42FA-B5A7-7C5838E72637

Q35050805-48300D65-57FA-48B2-8403-165552B0AA26

Q35050805-48E8D3A3-3316-4611-8A26-E067C81DFF61

P304

Q35050805-C368664E-E36B-4D5D-BF5C-C01C7612B433

P31

Q35050805-A08FA487-FD2C-4E99-BEE2-D4F7D40CB200

P356

Q35050805-78E59BD6-00BD-4C67-A3C6-3AFA10B94191

P433

Q35050805-C2831C81-5666-4D0D-B551-BB680386B02C

P478

Q35050805-862B90A6-26B2-4B15-AA02-31D0A644ACC1

P577

Q35050805-6A04EB18-E2A2-40E4-B002-526878D38653

P5875

Q35050805-79BBB457-192A-47B0-8A93-035A3B5A4836

P698

Q35050805-114682EC-8BAA-45D7-AAAE-E9645E62D8FB

P932

Q35050805-2C75481C-4BAF-4D4F-BA8E-1CA004618D30

P356

P1433

World journal of nephrology

P1476

Are phosphodiesterase type 5 i ...... benign prostatic hyperplasia?

@en

P2093

Jong Kwan Park

http://www.w3.org/2001/XMLSchema#string

Li Tao Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy and safety of tadalafil 5 mg once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: subgroup analyses of pooled data from 4 multinational, randomized, placebo-controlled clinical studies.

Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial.

American Urological Association and European Association of Urology guidelines in the management of benign prostatic hypertrophy: revisited.

Guidelines on erectile dysfunction.

Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial.

EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction.

Nitric oxide/cGMP-mediated effects in the outflow region of the lower urinary tract--is there a basis for pharmacological targeting of cGMP?

EAU Guidelines on erectile dysfunction: an update.

The nitric oxide pathway in the human prostate: clinical implications in men with lower urinary tract symptoms.

The relationship between erectile dysfunction and lower urinary tract symptoms and the role of phosphodiesterase type 5 inhibitors.

P304

138-147

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.5527/WJN.V4.I1.138

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P577

2015-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

272097169

http://www.w3.org/2001/XMLSchema#string

P698

25664256

http://www.w3.org/2001/XMLSchema#string

P932

4317624

http://www.w3.org/2001/XMLSchema#string